Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD)

Journal of Chemotherapy

Volumn 22, Issue 5, 2010, Pages 291-297

  Butorac Petanjek, Bojana ^a   Parnham, M J ^b   Popovic Grle S ^a  

^a University Hospital for Lung Diseases Jordanovac   (Croatia)

^b MediMlijeko doo   (Croatia)

Author keywords

Antibiotics; Bacteria; COPD; Exacerbation; Guidelines

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; STEROID; TIOTROPIUM BROMIDE; UREIDOPENICILLIN;

AIR POLLUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL SINUSITIS; BACTERIAL VIRULENCE; BACTERIUM; CAUSE OF DEATH; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; EMERGENCY TREATMENT; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEALTH CARE; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTIOUS COMPLICATION; INTENSIVE CARE UNIT; LUNG FUNCTION; MEDICAL DECISION MAKING; MORAXELLA CATARRHALIS; MORTALITY; PATIENT COMPLIANCE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SMOKING; SPUTUM; STREPTOCOCCUS PNEUMONIAE; VIRUS;

EID: 78651385411     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.5.291     Document Type: Review

References (87)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-1504.
2. Global Initiative for Chronic Obstructive Lung Disease 2005. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: executive summary. National Heart, Lung and Blood Institute / World Health Organization. Available at www.goldcopd.com. Updated November 2008.
3. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 2004; 101: 10143-10148. (Pubitemid 38891209)
4. Whitney AR. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896-1901.
5. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Thorac Soc 2005; 2: 26-33.
6. Sharma S, Anthonisen N. Role of antimicrobial agents in the management of exacerbations of COPD. Treat Respir Med 2005; 4: 153-167.
7. Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thor Soc 2004; 1: 73-76.
8. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
9. Vijayasaratha K, Stockley RA. Causes and management of exacerbations of COPD. Breathe 2007; 3: 251-263.
10. Macintyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 530-535.
11. Sykes A, Mallia P, Johnston SL. Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 642-646.
12. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 554-564. (Pubitemid 47547851)
13. Hagedorn SD. Acute exacerbation of COPD. How to evaluate severity and treat the underlying cause. Postgrad Med 1992; 91: 105-112.
14. Wedzicha JA, Donaldson GC. Exacerbation of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
15. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852-1857.
16. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26: 234-241.
17. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Th Soc 2004; 1: 115-120.
18. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Resp Rev 2005; 14: 32-38.
19. Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129 (16): 317-324.
20. Tumkaya M, Atis S, Ozge C et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2007; 101: 729-737.
21. Hurst JR, Perera WR, Wilkinson TMA, et al. Exacerbation of chronic obstructive pumonary disease pan-airway and systemic inflammatory indices. Proc Am Thorac Soc 2006; 3: 481-482.
22. Ras G, Wilson R, Todd H, et al. The effect of bacterial products on neutrophil migration in vitro. Thorax 1990; 45: 276-280.
23. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Resp J 2007; 29: 1224-1238.
24. Stockley RA, O'Brien C, Pye A. et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001; 117: 1638-1645.
25. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am Rev Respir Crit Care Med 2001; 163: 349-355.
26. Kanner RE, Anthonisen NR, Connett JE for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.
27. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
28. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143-149.
29. Grossman RF. Use of guidelines and risk stratification in acute exacerbation of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2000; 21: 113-122.
30. Martinez FJ, Han MK, Flaherty K, et al. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther 2006; 4: 101-124.
31. Duong M, Simard M, Bergeron Y, et al. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMP 3004. Antimicrob Agents Chemother 2001; 45: 252-262.
32. Murphey TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002; 19: 761-775.
33. Davies DG, Parsek MR, Pearson JP, et al. The involvement of cell-to-cell signals in the development of bacterial biofilm. Science 1998; 280:295-298.
34. Rakhimova E, Wiehlmann L, Brauer AL, et al. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 2009; 200: 1928-1935.
35. Juan C, Gutierrez O, Renom F, at al. Chronic respiratory infections by mucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem. Antimicrob Agents Chemother 2008; 52 (6): 2285-2286.
36. Lanotte P, Watt S, Mereghetti L, et al. Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol 2004; 53: 73-81.
37. Malloy JL, Veldhuizen RA, Thibodeaux BA, et al. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. Am J Physiol Lung Cell Mol Physiol 2005; 288: 409-418.
38. Beatty AL, Malloy JL, Wright JR. Pseudomonas aeruginosa degrades pulmonary surfactant and increases conversion in vitro. Am J Respir Cell Mol Biol 2005; 32: 128-134.
39. Wellinghausen N, Straube E, Freidank H, et al. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. Int J Med Microbiol 2006; 296: 485-491.
40. Guideline for The Management of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases (AECOPD) 2000. Alberta Clinical Guideline working group. Updated 2006. http://www.topalbertadoctors.org/PDF/completeset/Bronchitis/ AECOPD-guideline.pdf (last viewed 17.02.2009)
41. Keith ER, Podmore RG, Anderson TP, et al. Characteristrics of Streptococcus pseudopneumoniae isolated from purulent sputum samples. J Clin Microbiol 2006; 44: 923-927.
42. Bogaert D, van der Valk P, Ramdin R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004; 72: 818-823.
43. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med 2002; 347: 465-471.
44. Fernaays MM, Lesse AJ, Sethi S et al. Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease. Infect Immun 2006; 74: 3366-3374. (Pubitemid 43794526)
45. Murphy TF, Brauer AL, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.
46. Woodhead M, Blasi F, Ewing S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Resp J 2005; 26: 1138-1180.
47. Brunton S, Carmichael BP, Colgan R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care 2004; 10: 661-662.
48. Falagas ME, Avgeri SG, Matthaiou DK et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008; 62: 442-450.
49. Schuetz P, Christ-Crain M, Thomann R, at al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomised controlled trial. JAMA 2009; 302 (10): 1059-1066.
50. Larsson L, Lode H, Rollof J. Use of antibiotics, antioxidants, mucolytics and vaccines in the therapy of chronic obstructive pulmonary disease. In: Postma DS, Siafakas NM, editors. Management of chronic obstructive pulmonary disease. Eur Respir Mon 1998; 7: 163-168.
51. Dever LL, Shashikumar K, Johanson WG Jr. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002; 11: 911-925.
52. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
53. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447-455.
54. Samore MH, Lipsitch M, Alder SC, et al. Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol 2006; 163: 160-170.
55. Morand B, Mühlemann K. Heteroresistance to penicillin in Streptococcus pneumoniae. Proc Natl Acad Sci USA 2007; 104: 14098-14103.
56. Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63 (3);511-519.
57. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents pment in the major respiratory pathogens. Int J Antimicrob Agents 2007;30:135-138.
58. Vila-Corcoles A, Bejarano-Romero F, Salsench E. Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia. MBC Infect Dis 2009; 9: 36.
59. Imöhl M, Rene Reinert R, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int J Med Microbiol 2010; (Epub ahed of print)
60. Mazzariol A, Koncan R, Bahar G, et al. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. J Chemother 2007; 19(5): 500-507.
61. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXI-AKTIV Study). Int J Antimicrob Agents 2009; 33(1): 52-57.
62. Bishai WR. Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev Anti-infect Ther 2006; 4: 405-416.
63. Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics: The example of tilmicosin. Can J Vet Res 2010; 74(1): 1-10.
64. Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41(2): 177-185.
65. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2006; 12: 440-444.
66. uli O, Erakovi V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-229.
67. Hele DJ, Belvisi MG. Novel therapies for the treatment of inflammatory airway disease. Expert Opin Investig Drugs 2003; 12: 5-18.
68. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opinion Pharmacol 2008; 8: 286-291.
69. Basygit I, Yildiz F, Ozkara SK, et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data (September). Ann Pharmacother 2004; 38: 1400-1405.
70. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD. Treat Resp Med 2004; 3: 59-65.
71. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteria in clinical COPD. Resp Med 2005; 99: 208-215.
72. Parnham MJ, uli O, Erakovi V, at al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by shortterm azithromycin treatment. Eur J Pharmacol 2005; 517: 132-143.
73. Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther doi: 10.1016/j.pupt.2009.12.002
74. Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect 2006; 12 (3): 42-54.
75. Riesbeck K. Immunomodulating activity of quinolones: review. J Chemother 2002; 14: 3-12.
76. Soler N, Augusti C, Angrill J, et al. Bronchoscopic validation of the significance of sputum virulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35.
77. Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2005; Issue 1., Art. No.: CD001288.pub2. DOI: 10.1002/14651858.CD001288.pub2
78. Davies L, Angus LM, Calverly PM. Oral corticosteroids in patients admitted to hospital with exacerbation of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460.
79. Decramer M, Ferguson G. Clinical safety of long-acting beta 2-agonist and inhaled corticosteroid combination therapy in COPD. COPD 2006; 3: 163-171.
80. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
81. Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 2001; 120: 258-270.
82. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003; 16: 321-325.
83. Chen ZH, Kim HP, Ryter SW, et al. Identifying targets for COPD treatment through gene expression analyses. Int J Chron Obstruct Pulmon Dis 2008; 3: 359-370.
84. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
85. Molfino NA. Genetic predisposition to accelerated decline of lung function in COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 117-119.
86. Gaschler GJ, Bauer CM, Zavitz CC, et al. Animal models of chronic obstructive pulmonary disease exacerbations. Contrib Microbiol 2007; 14: 126-141.
87. Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2005; 2: 361-366.